2022-RA-966-ESGO Tolerance of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with relapse advanced ovarian carcinoma: a phase I study with expansion cohort (ICONIC)
P. Corbaux, B. You, Naoual Bakrin, O. Glehen, G. Freyer
{"title":"2022-RA-966-ESGO Tolerance of intraperitoneal (IP) nivolumab after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients (pts) with relapse advanced ovarian carcinoma: a phase I study with expansion cohort (ICONIC)","authors":"P. Corbaux, B. You, Naoual Bakrin, O. Glehen, G. Freyer","doi":"10.1136/ijgc-2022-esgo.609","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"47 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ovarian cancer and other gynecologic malignancies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}